Consensus statement on the treatment of transplant eligible patients with newly diagnosed multiple myeloma in New Zealand

The New Zealand Myeloma Interest Group is comprised of representative haematologists from District Health Boards around the country with a special interest and expertise in MM.

We reviewed the currently available evidence, including randomised controlled trials, retrospective data and conference abstracts, and interpreted these in the context of treatment options available in New Zealand to form a recommendation that is best suited for our population.